← board
ABT
distress 2/10 · well-funded / low risk$100.210%today-27% from 52w high
Revenue
$11164M
Liquidity
$8385M
Runway
—
Shares 1y
+0%
Price & events
-6.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
+1.4%
1W
+11.5%
1M
+9.1%
3M
-5.5%
6M
-18.5%
1Y
+0.6%
2Y
-8.6%
5Y
+2.4%
All
Overview
- Market Cap
- $174.55B
- Enterprise Value
- $197.38B
- Volume
- 1.15M
- 52 Week Range
- $82.56 – $137
- Total Shares
- 1.74B
- Float Shares
- 1.73B
- Short %
- 1.50%
- % Held by Insiders
- 0.49%
- % Held by Institutions
- 82.47%
- RVOL
- 0.08x
- Beta
- 0.61
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026-10-14Confirmed 100%earningsEarningsEarnings releaseyahoo
- June 4, 2026 at 9:30 A.M.conferencedata presentationsecondaryFinal settlement hearing for derivative lawsuit.SEC 8-K
- 2026-03-23partnershipAbbott completed acquisition of Exact Sciences, making it a wholly owned subsidiary.SEC 8-K
- 2025-11-19partnershipExact Sciences · Abbott agreed to acquire Exact Sciences for $105 per share in cash.SEC 8-K
Approved drugs (14)
- DEPAKOTE ERDIVALPROEX SODIUM2002 · Prescription
- MERIDIASIBUTRAMINE HYDROCHLORIDE1997 · Discontinued
- NORVIRRITONAVIR1996 · Discontinued
- HYTRINTERAZOSIN HYDROCHLORIDE1994 · Discontinued
- PROSOMESTAZOLAM1990 · Discontinued
- DEPAKOTE CPDIVALPROEX SODIUM1990 · Discontinued
- IBUIBUPROFEN1989 · Discontinued
- HYTRINTERAZOSIN HYDROCHLORIDE1987 · Discontinued
- AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINERAMINO ACIDS1986 · Discontinued
- AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINERAMINO ACIDS1986 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $118 (+18% upside) · 24 analysts
- 2026-07-17Piper SandlerOverweight
- 2026-07-17JP MorganOverweight
- 2026-07-17Wells FargoOverweight
- 2026-07-17TD CowenBuy
- 2026-07-17Evercore ISI GroupOutperform
- 2026-07-17RBC CapitalOutperform
Competitors
- none identified
Recent news
- 2026-07-23Abbott Laboratories (NYSE:ABT) Faces A Profit Test - Kalkine Media
- 2026-07-23Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating - marketscreener.com
- 2026-07-23Abbott Laboratories (ABT) Is Up 12.7% After Revenue Rises But Earnings Shrink In Q2 2026 - simplywall.st
- 2026-07-23Same Industry, Less Money: What Boston Scientific and ResMed Offers That Abbott Laboratories Does Not - Trefis
- 2026-07-23Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value? - Yahoo Finance
- 2026-07-22Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition - MSN
- 2026-07-22Leerink Partners Adjusts Price Target on Abbott Laboratories to $109 From $106, Maintains Market Perform Rating - marketscreener.com
- 2026-07-22Cancer Diagnostics Breached At Abbott As 2026 Medtech Cyberattack Run Continues - insights.citeline.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.